Literature DB >> 1122174

Brain peroxidase and catalase in Parkinson disease.

L M Ambani, M H Van Woert, S Murphy.   

Abstract

Peroxidase and catalase activities were determined in various regions of parkinsonian brains and control brains from patients with nonneurological diseases. The highest peroxidase activity was localized in the substantia nigra of the normal brain. In Parkinson disease, the peroxidase activity was decreased in the substantia nigra, caudate and putamen. Catalase activity was also reduced in the substantia nigra and putamen of the parkinsonian brain. These enzyme changes may be causally related to the degeneration and depigmentation of the substantia nigra neurons in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122174     DOI: 10.1001/archneur.1975.00490440064010

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  49 in total

1.  Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease.

Authors:  S M Kulich; C T Chu
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

2.  Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Authors:  Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

Review 3.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

4.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

Review 5.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 6.  Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading.

Authors:  Dhruvitkumar S Sutaria; Mohamed Badawi; Mitch A Phelps; Thomas D Schmittgen
Journal:  Pharm Res       Date:  2017-03-17       Impact factor: 4.200

7.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

Review 8.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

10.  Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum.

Authors:  Hideaki Kabuto; Masao Amakawa; Mitsumasa Mankura; Tomoko T Yamanushi; Akitane Mori
Journal:  Neurochem Res       Date:  2009-02-15       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.